Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments. Candidates for a novel form of specific immunotherapy

Susanne Vrtala, Kora Hirtenlehner, Luca Vangelista, Annalisa Pastore, Hans Georg Eichler, Wolfgang R. Sperr, Peter Valent, Christof Ebner, Dietrich Kraft, Rudolf Valenta

Research output: Contribution to journalArticlepeer-review

203 Citations (Scopus)

Abstract

A novel approach to reduce the anaphylactic activity of allergens is suggested. The strategy makes use of the presence of conformational immunoglobulin E (IgE) epitopes on one of the most common allergens. The three dimensional structure of the major birch pollen allergen, Bet v 1, was disrupted by expressing two parts of the Bet v 1 cDNA representing amino acids 1-74 and 75-160 in Escherichia coli. In contrast to the complete recombinant Bet v 1, the fragments showed almost no allergenicity and exhibited random coil conformation as analyzed by circular dichroism. Both nonanaphylactic fragments induced proliferation of human Bet v 1-specific T cell clones, indicating that they harbored all dominant T cell epitopes and therefore may be considered as a basis for the development of a safe and specific T cell immunotherapy.

Original languageEnglish
Pages (from-to)1673-1681
Number of pages9
JournalJournal of Clinical Investigation
Volume99
Issue number7
DOIs
Publication statusPublished - Apr 1 1997

Keywords

  • Bet v 1
  • histamine release
  • major birch pollen allergen
  • recombinant allergen fragments
  • skin testing

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments. Candidates for a novel form of specific immunotherapy'. Together they form a unique fingerprint.

Cite this